Short answer
Editas Medicine, Inc. (EDIT) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). FDA approval to initiate first-in-human EDIT-401 trial in hyperlipidemia.
Editas Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA approval to initiate first-in-human EDIT-401 trial in hyperlipidemia
- Clinical-stage milestone enabling initial human safety and efficacy testing
- EDIT-401 trial start creates development catalyst, with future value dependent on clinical results
Item 8.01 · Other Events
- Australia approval enables Phase 1/2 Strive trial of EDIT-401 in heterozygous familial hypercholesterolemia
- EDIT-401 targets LDLR upregulation, with approximately 90% reductions in LDL-C, Lp(a), and ApoB in non-human primates
- Approximately 90% LDL-C reduction maintained over 10 months in ongoing non-human primate study
- Initial safety and tolerability data expected in Q1 2027, with Part 1 topline data later in 2027
- New Zealand approval remains pending, creating enrollment and execution uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Editas Medicine, Inc. 8-K filings
Get the next EDIT 8-K as it lands
Follow EDIT for push alerts, or ask the research agent what this filing means.